Paul R. Edick, See Remarks at Xeris Biopharma Holdings, Inc. (XERS), bought 20,000 shares at $2.28 ($46K) on 2021-11-15, disclosed to the SEC on 2021-11-16.
Open-market purchase of $46k XERS by See Remarks. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| XERS | BUY | 2022-05-13 | $140K | — | Filing → |
| XERS | BUY | 2021-11-12 | $416K | — | Filing → |
| XERS | BUY | 2020-12-10 | $41K | — | Filing → |